Editorial Note: The findings in this report indicate that, in 2005, ED visits for nonfatal self-inflicted injuries were less common among adults aged >65 years than among younger adults. However, older adults were more likely than younger adults to be hospitalized after ED treatment for an injury related to suicidal behavior. In addition, for older adults whose visits were related to suicidal behavior, alcohol use at the time of the injury was less frequently reported.
Nonfatal Self-Inflicted Injuries Among Adults Aged >65 YearsUnited States, 2005
In 2005, an estimated 372,722 persons in the United States were treated in hospital emergency departments (EDs) for intentional, nonfatal self-inflicted injuries (1) . Nonfatal self-inflicted injuries are most common among adolescents and young adults (2) ; few studies have investigated these types of injuries among adults aged >65 years. However, older adults are one of the fastest-growing population groups in the United States and can require more extensive and more costly medical treatment than younger adults. To characterize ED visits for nonfatal self-inflicted injuries among U.S. adults aged >65 years, CDC analyzed ED visits for 2005 using data from the National Electronic Injury Surveillance System All Injury Program (NEISS-AIP). This report summarizes the results of that analysis, which indicated that, in 2005, adults aged >65 years made an estimated 7,105 visits to EDs (i.e., 19.3 visits per 100,000 population) for nonfatal self-inflicted injuries, and ED health-care providers attributed 80.4% of these visits to suicidal behavior. In addition, a significantly higher percentage of adults aged >65 years compared with younger adults were hospitalized after ED visits for suicidal behavior. Comprehensive prevention strategies that combine community outreach, crisis intervention, and clinical management are needed to decrease morbidity and mortality from suicidal behavior among older adults.
NEISS is operated by the U.S. Consumer Product Safety Commission and collects data about treatment of patients in U.S. hospital EDs for consumer-product-related injuries.* The expanded system, NEISS-AIP, collects data about treatment of patients for all types and causes of injuries in U.S. hospital EDs, regardless of whether the injuries are related to consumer products. NEISS-AIP includes data from 66 of the 100 NEISS hospitals that were selected as a stratified probability sample of all hospitals in the United States and its territories with a minimum of six beds and a 24-hour ED (3, 4) . Data are weighted by the inverse of the probability of selection to produce national estimates (3) . NEISS-AIP provides data on approximately 500,000 injuryrelated ED cases each year (3) . Estimates for this report were based on weighted data for 4,478 nonfatal selfinflicted injuries for which persons aged >20 years were treated in EDs during 2005. The weighted values were used to provide annual estimates for adults aged 20-34 years, 35-49 years, 50-64 years, and >65 years.
NEISS-AIP defines injuries as bodily harm that results from acute exposure to an external force or substance and includes unintentional or violence-related causes (2) . Cases are excluded if the ED visit is for unintended adverse effects of therapeutic drugs or surgical and medical care or the principal diagnosis is unknown or is an illness, pain only, psychological harm only (e.g., anxiety and depression), or contact dermatitis associated with exposure to plants or consumer products (2, 5) . Injuries are classified into mutually exclusive categories according to intent of injury (i.e., unintentional, assault, self-inflicted, and legal intervention † ) (2) . Data on sex, race/ethnicity, ED discharge disposition (i.e., treated then released, transferred then released, hospitalized, or left against medical advice or before being treated), and mechanism of injury (e.g., by cutting or piercing, poisoning, or a firearm gunshot) also are collected; mechanisms of injury are classified into major external cause-of-injury groups (5,6) using definitions consistent with International Classification of Diseases, Ninth Revision, Clinical Modifications guidelines (7) .
To categorize self-inflicted injuries by intent of injury, CDC analyzed screening forms that were completed by trained NEISS hospital coders using ED patient charts. The forms included information about 1) the ED clinician's description or diagnosis of the injury event, such as whether the visit resulted from suicidal behavior (i.e., intent to die was demonstrated or expressed by the patient) or selfabusive behavior (i.e., self-injurious behavior, such as selfmutilation, without the intent to die); 2) existing medical and psychiatric conditions of the patient (e.g., clinical depression, alcohol abuse, or substance abuse) as reported by patients or their relatives or friends; and 3) alcohol or recreational drug use at the time of the injury as determined by hospital staff members or laboratory reports.
During 2005, an estimated 7,105 ED visits for nonfatal self-inflicted injuries occurred among older adults (i.e., persons aged >65 years) (rate: 19.3 per 100,000 population), and 80.4% of these visits resulted from suicidal behavior ( Table 1) . Rates did not differ significantly between older adult men and women. Older adults had too few visits for self-abusive behavior to estimate a national rate. For all adult age groups, the majority of the ED visits for nonfatal self-inflicted injuries occurred among nonHispanic whites.
Among ED visits attributed to suicidal behavior, a significantly higher percentage of older adults (70.6%) were hospitalized after ED care than adults aged 20-34 years (42.8%) ( Table 2 ). The most common mechanism of injury related to suicidal behavior among all age groups was poisoning. Alcohol use at the time of the injury was less common among adults aged >65 years (15.1%) than among adults aged 20-34 years (28.6%) and 25-49 years (34.9%). As with the younger age groups, the majority of older adults (73.7%) who visited an ED for suicidebehavior-related injury had a history of depression.
poisoning, the most common cause for ED visits among all age groups for nonfatal suicidal behavior.
The findings in this report are subject to at least five limitations. First, small numbers of ED visits among particular subgroups of adults made certain rate estimates unstable. Second, classification of injuries caused by suicidal behavior was based on information solicited and recorded by ED health-care providers. Certain self-inflicted injuries that ED clinicians did not identify as related to suicidal behavior might later have been classified as such by clinicians who provided follow-up treatment, possibly resulting in an underestimation of those injuries. Third, although the screening tool was used to collect information regarding patient history of mental and behavioral conditions, information on mental distress, behavioral problems, or dementia at the time of the injury was not collected, thereby limiting the ability to understand certain circumstances preceding these events. Fourth, certain self-inflicted injuries from poisoning might have been misclassified as unintended adverse drug events and excluded from this study; therefore, self-inflicted injuries attributable to poisoning might be underestimated. Finally, because not all self-inflicted injuries result in ED visits, these findings likely underestimate the actual rates of selfinflicted injuries.
Available at http://www.suicidology.org/associations/1045/files/elderly.pdf. --* Data were weighted by the inverse of the probability of selection; therefore, certain numbers might not equal the total and certain percentages do not total 100% because of rounding. † Confidence interval. § Transferred to either a medical, psychiatric, or surgical ward; an intensive care unit; or another facility. ¶ National estimates are unstable because they are based on <20 cases or the coefficient of variation is >30%. ** Categories are not mutually exclusive.
Because the older adult population is the fastestgrowing age group of the U.S. population, the number of self-inflicted injuries in this group is likely to increase. These incidents can lead to more serious medical complications and hospitalizations than similar behaviors among younger adults because older adults are more likely to have comorbid conditions and longer recoveries. One study indicated that the average cost among older adults is approximately twice the average medical cost per case among adults aged 25-64 years ($9,749 versus $4,995) (9) .
The findings in this report illustrate the need for primary prevention measures that focus on the older adult population. Although few evaluated prevention programs have focused on older adults, promising strategies exist, such as better identification and treatment of clinical depression by primary-care physicians and increased social support for persons at risk (8) . For example, one study documented that training primary-care staff members to identify and treat adults for clinical depression was associated with lower suicide rates (8) . Additional research is needed to assess a broader scope of potential risk factors for suicidal behavior among older adults and to develop strategies for decreasing these risk factors. 4 Each year, cigarette smoking in the United States causes approximately 438,000 deaths and results in an estimated $167 billion in health-care costs plus lost productivity attributed to premature deaths (1). Although smoking cessation has major and immediate health benefits for persons of all ages (2), the benefit is greater the earlier in life a person quits. Persons who quit before the age of 35 years have a life expectancy similar to that of those who never smoked (3) . To assess the prevalence of current smoking among all adults and among those aged 18-35 years, and to assess the proportion of smokers aged 18-35 years who have quit or attempted to quit, CDC analyzed state and area data from the 2006 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report summarizes the results of that analysis, which indicated substantial variation in current cigarette smoking prevalence among the 50 states, the District of Columbia (DC), Puerto Rico (PR), and the U.S. Virgin Islands (USVI) (range: 9.1%-28.6%). The majority of current smokers aged 18-35 years reported that they had attempted to quit smoking during the past year (median: 58.6%; range: 48.0% [Nevada] to 69.2% [New Mexico]), and the median proportion of ever smokers aged 18-35 years who had quit smoking was 34.0% (range: 27.0% [Louisiana] to 47.9% [Utah]). Effective, comprehensive tobacco-use prevention and control programs should be continued and expanded to further reduce smoking initiation by young persons and to encourage cessation as early in life as possible (4, 5) .
BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized, U.S. civilian population aged >18 years. Estimates were weighted by age and sex distributions of each state or area population. Because BRFSS data are state-specific, national median prevalences are reported instead of national averages. The median response rate for the 50 states and DC was 51.4% (range: 35.1% [New Jersey] to 66.0% [Nebraska] ).
Respondents were asked, "Have you smoked at least 100 cigarettes in your entire life?" and "Do you now smoke cigarettes every day, some days, or not at all?" Ever smokers were defined as those who reported having smoked >100 cigarettes during their lifetime. Current smokers were defined as those who reported having smoked >100 cigarettes during their lifetime and who currently smoked every day or some days. Former smokers were defined as those who reported having smoked >100 cigarettes during their lifetime and who currently did not smoke at all. Attempted smoking cessation was assessed by asking those who smoked every day, "During the past 12 months, have you stopped smoking for 1 day or longer because you were trying to quit?" The percentage of ever smokers who had quit smoking was calculated by dividing the number of former smokers by the number of ever smokers.
Current Cigarette Smoking Prevalence
In 2006, the median prevalence of current cigarette smoking among adults in the 50 states and DC was 20.2%, with a nearly threefold difference among states with the lowest and highest prevalences ( Editorial Note: Substantial variations among states and territories were observed in smoking prevalence among adults overall and smoking prevalence and quitting among adults aged 18-35 years. These variations likely are attributed to differences in the distribution of socioeconomic determinants of smoking (e.g., race/ethnicity, age, and socioeconomic status), cultural norms, and the strength of tobacco-control programs and policies (5) . In 2006, Utah and USVI were the only areas to achieve the Healthy People 2010 objective to reduce overall adult smoking prevalence to <12% (objective 27-1a) (6); California achieved this objective among women only. Utah and USVI also were the only areas to achieve this objective among persons aged 18-35 years. The low prevalences in Utah and USVI might be a result of stronger social and cultural norms against tobacco use compared with other parts of the United States. The findings in this report indicate that in the 53 areas surveyed, the majority of current daily smokers aged 18-35 years had tried to quit during the past year. On average, approximately one third of persons aged 18-35 years who had ever smoked reported that they did not currently smoke. The rates differed between adults in the 18-35 years age group and the total adult population (CDC, unpublished data, 2007).
Early cessation should be encouraged because persons who quit before the age of 35 years have a life expectancy similar to that of never smokers (3). The longer young adults smoke, the more likely they are to develop adverse health effects that are not reversible. Young adults who smoke include persons who are just beginning to smoke, those who do not smoke daily, persons who are transitioning to daily smoking, and daily smokers who might or might not have tried to quit. Diverse strategies are needed to motivate these different groups to quit smoking, such as conducting sustained mass media campaigns, increasing the price of tobacco products, providing brief counseling by health-care professionals at every clinic visit, reducing out-of-pocket costs of smoking-cessation treatments, and offering telephone quitlines (4) . Similar to older adults, young adults usually try to quit on their own (7) . Among adolescent and young adult smokers aged 16-24 years who reported ever trying to quit, only 20% reported talking with a nurse, doctor, or dentist for assistance with their quit attempts, and even smaller proportions had used counseling (e.g., individual, group, or telephone counseling) or medications approved by the Food and Drug Administration (7) . Therefore, strategies also are needed to increase the use of effective cessation treatments among these smokers.
The findings in this report are subject to at least five limitations. First, BRFSS does not survey persons in households without landline telephones or those with wireless-only telephones, populations that might more likely include smokers (8, 9) . Wireless telephone use is highest among young adults and decreases with age (9) . Preliminary findings from the National Health Interview Survey indicate that approximately one in four adults aged 18-24 years and nearly one in three adults aged 25-29 years lived in households with only wireless telephones in 2006 (9) . The exclusion of persons with wireless-only telephone service might have led to the underestimation of smoking prevalence, particularly among those aged 18-35 years. Second, estimates for cigarette smoking are based on selfreport and are not validated by biochemical tests. However, self-reported data on current smoking status have high validity (8) . Third, the median response rate was 51.4% (range: 35.1%-66.0%). Lower response rates indicate a potential for response bias; however, BRFSS estimates for current cigarette smoking are comparable to smoking estimates from other surveys with higher response rates (8) . Fourth, the survey did not include information on the length of time between the quit attempt and the interview. Finally, the number of young adults who quit smoking was low; thus, certain estimates derived from statelevel data are unstable.
Effective interventions have been identified for preventing smoking initiation and increasing cessation rates (4), but they have not been implemented adequately by most states. Fully implementing comprehensive state tobacco-control programs as 
Update on Vaccine-Derived Polioviruses -Worldwide, January 2006-August 2007
In 1988, the World Health Assembly resolved to eradicate poliomyelitis worldwide. Subsequently, the Global Polio Eradication Initiative of the World Health Organization (WHO) reduced the global incidence of polio associated with wild polioviruses (WPVs) from an estimated 350,000 cases in 1988 to 1,998 reported cases in 2006 and reduced the number of countries that have never succeeded in interrupting WPV transmission to four (Afghanistan, India, Nigeria, and Pakistan) (1). However, because vaccine-derived polioviruses (VDPVs) can produce polio outbreaks in areas with low rates of Sabin oral poliovirus vaccine (OPV) coverage and can replicate for years in immunodeficient persons, enhanced strategies are needed to limit emergence of VDPVs and stop all use of OPV once 
Properties of VDPVs
VDPVs can cause paralytic polio in humans and the potential for sustained circulation of poliovirus. VDPVs resemble WPVs biologically (3) and differ from the majority of Sabin vaccine-related poliovirus isolates by having genetic properties consistent with prolonged replication or transmission. Because poliovirus genomes evolve at a rate of approximately 1% per year, Sabin vaccine-related isolates that differ from the corresponding OPV strain by more than 1% of nucleotide positions (usually determined by sequencing the genomic region encoding the major viral surface protein, VP1) are estimated to have replicated for at least 1 year after administration of an OPV dose. This is substantially longer than the normal period of vaccine virus replication of 4-6 weeks.
Poliovirus isolates can be distinguished by their three serotypes: type 1, type 2, and type 3. Isolates also can be divided into three categories, based on the extent of VP1 nucleotide sequence divergence from the corresponding Sabin OPV strain: 1) Sabin vaccine-like viruses (<1% divergent), 2) VDPVs (1%-15% divergent), and 3) WPVs (>15% divergent) (4) . VDPVs are further categorized as 1) circulating VDPVs (cVDPVs), which emerge in areas with inadequate OPV coverage; 2) immunodeficientassociated VDPVs (iVDPVs), which are isolated from persons with primary immunodeficiencies who have prolonged VDPV infections after exposure to OPV; and 3) ambiguous VDPVs (aVDPVs), which are either clinical isolates from persons with no known immunodeficiency or environmental isolates whose ultimate source has not been identified (3). Table) . † An additional 24 type 2 case isolates with 0.5%-1.0% VP1 divergence from the Sabin type 2 OPV strain and belonging to the same lineages as the cVDPV isolates were detected in eight of the nine northern states. At least 46 (49%) of the cVDPV isolates and closely related isolates were from Kano state, which has been a major reservoir for WPV type 1 (WPV1) and type 3 (WPV3) circulation (5) . Phylogenetic analysis based on sequences of the complete capsid region (2, 
FIGURE. Locations of polio outbreaks* associated with cVDPVs, persons excreting iVDPVs, and isolations of aVDPVs † -worldwide, 2005-2007
* All of the outbreaks were detected first by laboratory confirmation, using sequence data and evolutionary analyses, and followed elimination of the corresponding serotype of indigenous wild poliovirus, but with continued introduction of oral poliovirus vaccine (OPV) into communities with growing immunity gaps. † Vaccine-derived polioviruses (VDPVs) are categorized as 1) circulating VDPVs (cVDPVs), which emerge in areas with inadequate OPV coverage;
2) immunodeficient-associated VDPVs (iVDPVs), which are isolated from persons with primary immunodeficiencies who have prolonged VDPV infections after exposure to OPV; and 3) ambiguous VDPVs (aVDPVs), which are either clinical isolates from persons with no known immunodeficiency or environmental isolates whose ultimate source has not been identified. § The 2006-2007 outbreak in Nigeria included 69 cases associated with type 2 cVDPVs and 24 additional cases associated with type 2 viruses that were closely related to cVDPVs. Two other cases associated with cVDPVs were imported into Niger from Nigeria. Duration of iVDPV replication was estimated from the clinical record by assuming that exposure was from initial receipt of OPV. Duration of aVDPV replication was estimated from sequence data. ** Most cVDPV isolates from Nigeria and Myanmar were vaccine/nonvaccine recombinants; none of the iVDPV or aVDPV isolates appeared to be vaccine/nonvaccine recombinants. † † Excludes 24 isolates from acute flaccid paralysis (AFP) cases that were 0.5%- Syria. Syria has detected and investigated VDPVs since 2001 (3). In 2006, humoral and cell-mediated immunodeficiency was diagnosed in an AFP patient, and stool specimens collected 4-8 days after onset of paralysis were positive for type 2 iVDPV. Tests determined that none of five contacts were excreting poliovirus.
Kuwait and Egypt. An Egyptian child with severe combined immunodeficiency residing in Kuwait was determined to be excreting type 3 iVDPV. A second immunodeficient child in Egypt was infected with a different type 3 iVDPV and died.
aVDPVs
China. In June 2006, a type 1 aVDPV was isolated from an immunocompetent AFP patient and seven close contacts in rural Guangxi Province. Sequence diversity among the isolates was consistent with localized VDPV circulation (Table) . A type 3 aVDPV was isolated from a healthy patient in Shanghai in August 2006; subsequent stool specimens were negative. In addition, type 1 aVDPV was isolated from a child with AFP in Shanxi Province in 2007.
Israel . Despite follow-up investigations, no source for these VDPVs has been identified. Genetic properties of the isolates (highly diverse antigenic structures and absence of vaccine/nonvaccine recombination) are more similar to iVDPVs than to cVDPVs (6).
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Editorial Note: The close integration of AFP surveillance with detailed poliovirus characterization by the Global Polio Laboratory Network (3) has led to detection of VDPVs in more diverse settings and identification of key biologic and genetic properties of VDPVs. Further understanding through laboratory findings will be vital to improving strategies for managing risk factors associated with emergence of VDPVs (7).
Testing of the new molecular methods has been accelerated, which should increase substantially the sensitivity of laboratory screening for all VDPVs, especially type 2 VDPVs. Multiple Nigerian type 2 polioviruses in the recent outbreak had <1% VP1 divergence but shared distinctive nucleotide substitution patterns and recombination sites with the recognized cVDPVs, which indicated their epidemiologic role; all were associated with paralytic illness.
cVDPVs detected in 2006-2007 provide further evidence that the key risk factor for spread of VDPVs is low vaccination coverage (3, 4) . In Nigeria in 2005, 15%-50% of children aged <5 years with cVDPVs, in seven of the nine states, had not received an OPV dose. This was reduced to 6%-30% by the end of 2006 (5,9) through steadily improving SIAs (5). The low rates of routine tOPV coverage combined with the finding of multiple independent cocirculating cVDPV lineages in much of northern Nigeria suggest that conditions favorable for type 2 cVDPV emergence and spread existed in multiple locations in that part of the country. In Niger, routine tOPV coverage has been greater (89%) than in Nigeria (39%), and the 2006-2007 SIAs administered tOPV, which limited further VDPV transmission. In Myanmar, high rates of routine OPV coverage also appear to have limited cVDPV circulation, with cases reported only in low-coverage communities. Experience suggests that cVDPV outbreaks can be terminated if high OPV coverage can be achieved during follow-up SIAs (3). Outbreaks can be prevented by maintaining high polio vaccination coverage through routine vaccination and SIAs.
The first detections of iVDPVs and all of the long-term iVDPV chronic infections (>3 years) detected to date were in countries with high-income economies ¶ (e.g., Japan and countries in Western Europe and North America) (3). More recent reports of iVDPVs have come from countries with middle-income economies such as Argentina, Kazakhstan, Thailand, Iran, and Syria (3), with no evidence of chronic infections or spread of VDPVs to household or community contacts. Repeated detection of iVDPVs in varied settings underscores the continuing risks for iVDPV emergence as long as OPV is used. Unlike cVDPVs, which can be prevented from emerging by high rates of OPV coverage, iVDPVs potentially can arise any time a person with a primary immunodeficiency is exposed to OPV, either as an OPV recipient or as a contact of a recipient. The only way to prevent new iVDPV infections is to stop OPV use.
The environmental aVDPV isolates from Israel, as with those previously isolated from sewage in Estonia (type 3) and Slovakia (type 2) (3), likely are iVDPVs, based on their genetic and antigenic properties, and might have resulted in limited transmission to close contacts. However, measures to identify infected persons have been unsuccessful, and the possibility exists that the VDPV infections were asymptomatic.
Continued cVDPV outbreaks, emergence and detection of iVDPVs in certain persons with B-cell immunodeficiencies, and detection of aVDPVs in diverse settings underscore the risks associated with continuing use of OPV after WPV has been eradicated. However, until that time, OPV must be used at high rates of coverage to interrupt WPV transmission and prevent the spread of VDPVs, particularly in countries with low-income economies, high population densities, poor sanitation, and tropical climates. Although chronic iVDPV infections are rare, no effective means exist for clearing such infections (10) . Consequently, while working to interrupt all remaining WPV transmission, the Global Polio Eradication Initiative also must continue to reduce the risk for VDPV emergence and transmission by strengthening routine vaccination in underperforming countries,** developing strategies to clear iVDPV infections with new antiviral drugs (10), and refining strategies for stopping all OPV use after global eradication of WPVs (2,7).
Update: Influenza ActivityUnited States and Worldwide, May 20-September 15, 2007
During May 20-September 15, 2007, influenza A (H1), influenza A (H3), and influenza B viruses cocirculated worldwide and were identified sporadically in the United States. This report summarizes influenza activity in the United States and worldwide since the last MMWR update (1).
United States
In the United States, CDC uses nine systems for national influenza surveillance (2), six of which operate year-round: 1) World Health Organization (WHO) collaborating laboratories; 2) the National Respiratory and Enteric Virus Surveillance System (NREVSS); 3) the U.S. Influenza Sentinel Provider Surveillance System; 4) the 122 Cities Mortality Reporting System; 5) the Influenza-Associated Pediatric Mortality System, part of the National Notifiable Diseases Surveillance System (NNDSS); and 6) novel influenza A virus case reporting through NNDSS. Data from these six systems are included in this report.
During May 20-September 15, 2007,* WHO and NREVSS collaborating laboratories in the United States tested 21,029 respiratory specimens for influenza viruses; 398 (1.9%) were positive ( Figure) . Of these, 330 (83%) were influenza A viruses, and 68 (17%) were influenza B viruses. Of the influenza A viruses, 152 (46%) were subtyped: 67 (44%) were influenza A (H1) viruses, and 85 (56%) were influenza A (H3) viruses. Influenza viruses were reported from 22 states in eight of the nine public health surveillance regions. However, 200 (50%) of all the influenza viruses, including 63 (94%) of the 67 influenza A (H1) viruses, were reported from Hawaii, and 100 (25%) were reported from Florida. Of the 398 influenza viruses reported during the summer months, only 124 (31%) were reported during August and the first half of September. Among this subset of viruses, 105 (85%) were influenza A, and 19 (15%) are influenza B.
During May 20-September 15, data from the U.S. Influenza Sentinel Provider Surveillance System indicated that the weekly percentage of patient visits to U.S. sentinel providers for influenza-like illness (ILI) † remained below the national baseline § of 2.1% and ranged from 0.6% to 1.0%. The percentage of deaths attributed to pneumonia and influenza (P&I) as reported by the 122 Cities Mortality Reporting System was below the epidemic threshold. ¶ One influenza-associated pediatric death occurred during No. of isolates Percentage positive † Defined as a temperature of >100.0°F (>37.8°C), oral or equivalent, and cough and/or sore throat, in the absence of a known cause other than influenza. § The national baseline is the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. Noninfluenza weeks are those in which <10% of laboratory specimens are positive for influenza. ¶ The expected seasonal baseline proportion of P&I deaths reported by the 122 Cities Mortality Reporting System is projected using a robust regression procedure in which a periodic regression model is applied to the observed percentage of deaths from P&I that occurred during the preceding 5 years. The epidemic threshold is 1.645 standard deviations above the seasonal baseline.
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June and was reported to the Influenza-Associated Pediatric Mortality Reporting System. Two human cases of novel influenza A were reported to NNDSS. Both persons were infected with swine influenza virus and were infected by handling ill pigs at a county fair in Ohio. Both recovered from their illness.
Worldwide
During May 20-September 15, influenza A (H1), influenza A (H3), and influenza B viruses cocirculated worldwide. Influenza A (H3) viruses predominated in Asia; however, influenza A (H1) and B viruses also were reported. In Africa, influenza A viruses predominated, with approximately equal numbers of influenza A (H1) and A (H3) viruses reported and a smaller number of influenza B viruses identified. In Europe and North America, small numbers of influenza A and influenza B viruses were reported. In Oceania, influenza A viruses predominated. Influenza A (H3) viruses were reported more frequently than influenza A (H1) viruses in Australia and New Caledonia; however, in New Zealand, influenza A (H1) viruses predominated. In South America, influenza A (H3) viruses were most commonly reported, although influenza B viruses also were identified.
Antigenic Characterization of Influenza Virus Isolates
The WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, located at CDC, analyzes influenza virus isolates received from laboratories worldwide. Of four influenza A (H1) viruses that were collected during May 20-September 8 (three from Asia and one from Europe) and analyzed at CDC, all four (100%) 
Human Infections with Avian Influenza A (H5N1) Viruses
During May 20-September 10, 2007, a total of 21 human cases of avian influenza A (H5N1) infection were reported to WHO from four countries (China, Egypt, Indonesia, and Vietnam). Fourteen (67%) of the cases were fatal. Since December 1, 2003, a total of 328 human avian influenza A (H5N1) infection have been reported to WHO (3). Of these, 200 (61%) were fatal (Table) . All cases were reported from Asia (Azerbaijan, Cambodia, China, Indonesia, Iraq, Laos, Thailand, Turkey, and Vietnam) and Africa (Djibouti, Egypt, and Nigeria). In addition, no human case of avian influenza A (H5N1) virus infection has been identified in the United States. Vaccination is the best method for preventing influenza and its potentially severe complications. In the United States, the influenza vaccine can be administered to any person aged >6 months who wants to reduce the likelihood of becoming ill with influenza or transmitting the virus to others. Annual influenza vaccination is targeted toward persons at increased risk for influenza-related complications and severe disease (e.g., children aged 6-59 months, pregnant women, persons aged >50 years, and persons aged 5-49 years with certain chronic medical conditions) and their close contacts (e.g., health-care workers and household contacts) (4) . In addition, all children aged 6 months to <9 years who have never received influenza vaccination should receive 2 doses of influenza vaccine (4) . For the 2007-08 influenza season, vaccine supplies are projected to be plentiful in the United States; therefore, influenza vaccination can proceed for all persons, whether healthy or at high risk, either individually or through mass campaigns, as soon as vaccine is available.
Although many of the recently examined influenza A (H3) viruses show reduced reactivity with sera produced against the A/Wisconsin/67/2005 (H3N2) vaccine strain (the H3N2 component of the 2007-08 influenza vaccine), vaccination is still the best means of protection against influenza and influenza-related complications. Even in years in which the match between the vaccine strains and circulating strains is not exact and protection against illness is reduced, the vaccine can still mitigate the severity of illness and reduce the likelihood of severe outcomes such as hospitalization and death.
Although vaccination is the best method for preventing and reducing the impact of influenza, antiviral medications are a valuable adjunct. For patients who consult a healthcare provider within 48 hours of illness onset, antiviral medications can reduce the duration of illness and might reduce the likelihood of complications. Antivirals also can be used to prevent influenza in persons who have not received vaccine and to control outbreaks in institutions or group residential settings such as nursing homes.
On September 19, 2007, the Food and Drug Administration (FDA) approved the live, attenuated influenza vaccine (LAIV), FluMist ™ , for use in healthy children aged 2-4 years (i.e., 24-59 months). Vaccination providers should ask the parents or guardians of these children about wheezing and should not use LAIV in children who have recurrent wheezing. LAIV, which is administered as a nasal spray, had already been approved for healthy children aged >5 years and healthy adults aged <50 years. Other FDAapproved changes in the use of FluMist for persons of all approved ages include 1) a reduction in the volume of vaccine used to 0.1 mL per nostril, 2) a reduction in the minimum dose spacing to 4 weeks for children who require 2 doses, and 3) a change in the temperature requirements for shipping and storage of the vaccine (now 2-8°C [35-46°F]). Trivalent inactivated influenza vaccine, which is administered as an intramuscular injection, may be used for any person aged >6 months, including those with high-risk conditions (4) .
Two cases of human infection with swine influenza virus were reported in the United States during August. Although human infection with swine influenza is uncommon, sporadic cases occur in most years, usually among persons in direct contact with ill pigs or who have been in places where pigs might have been present (e.g., agricultural fairs, farms, or petting zoos). The sporadic cases detected in recent years have not resulted in sustained human-to-human transmission or community outbreaks; however, human infections with swine influenza viruses or any other nonhuman or novel influenza virus should be identified quickly and investigated. Clinicians should consider swine influenza A in the differential diagnosis among patients with ILI who have had recent contact with pigs. Testing of respiratory specimens from these patients for influenza virus should be coordinated with the state health department laboratory. In January 2007, the executive committee of the Council of State and Territorial Epidemiologists (CSTE) voted to make human infection with a novel influenza A virus, including swine influenza viruses, a nationally notifiable condition, and the proposal was approved by CSTE in June (5, 6) .
In collaboration with local and state health departments, CDC continues to recommend enhanced surveillance for possible influenza A (H5N1) infection among travelers with 
Notice to Readers

World Heart Day -September 30, 2007
Heart disease and stroke, which are associated with risk factors such as high blood pressure, high blood cholesterol, smoking, diabetes, obesity, poor nutrition, and physical inactivity, are the world's biggest killers, claiming 17.5 million lives a year. Approximately 80% of these deaths occur in low-and middle-income countries.
The eighth annual World Heart Day, sponsored by World Heart Federation member organizations in approximately 100 countries, will be observed on September 30. This year's theme is Team Up for Healthy Hearts. Based in Geneva, Switzerland, the World Heart Federation is a nongovernmental organization committed to promoting longer and better lives through prevention and control of heart disease and stroke. World Heart Day activities will include health checks; organized walks, runs, and fitness sessions; public talks; stage shows; scientific forums and exhibitions; concerts; carnivals; and sports tournaments.
Preventive measures can reduce the risk for heart disease and stroke. At the community level, the American Heart Association (AHA) recommends 1) creating school, worksite, and health-care facility education programs; 2) developing policies that ensure access to screening, referral, and counseling services for stroke and heart disease risk factors; and 3) ensuring access to healthy foods and safe environments for physical activity (1). In addition, CDC has developed a plan for taking effective action through comprehensive public health partnerships and programs (2) .
Information regarding CDC heart disease prevention programs is available at http://www.cdc.gov/dhdsp. Information about World Heart Day and the World Heart Federation is available at http://www.world-heart-federation.org/whatwe-do/world-heart-day. Additional information regarding heart disease is available from AHA at http://www.american heart.org. 
Notice to Readers
Clinical Vaccinology CourseNovember 9-11, 2007
CDC and four other national organizations are collaborating with the National Foundation for Infectious Diseases (NFID), Emory University School of Medicine, and the Emory Vaccine Center to sponsor a Clinical Vaccinology Course, November 9-11, 2007, at the Hyatt Regency Bethesda Hotel in Bethesda, Maryland. Through lectures and interactive presentations, the course will focus on new developments and concerns related to the use of vaccines in pediatric, adolescent, and adult populations. Leading infectious-disease experts, including pediatricians, internists, and family physicians will present information on newly available vaccines, vaccines under development, and older vaccines whose continued administration is essential to improving disease prevention.
This course is specifically designed for physicians, nurses, nurse practitioners, physician assistants, vaccine-program administrators, and other health-care professionals interested in the clinical aspects of vaccinology. The course also might be useful for health-care professionals involved in prevention and control of infectious diseases, including federal, state, and local public health officials.
Continuing education credits will be offered. Information regarding the preliminary program, registration, and hotel accommodations is available at http://www.nfid.org/ conferences/idcourse07, or by e-mail (idcourse@nfid.org), fax (301-907-0878), telephone (301-656-0003, ext. 19), or mail (NFID, 4733 Bethesda Avenue, Suite 750, Bethesda, MD 20814-5228). In 2004, lung cancer was the leading cause of death from cancer both for men (31.3% of all cancer deaths among men) and women (25.6% of all cancer deaths among women). The second leading cause for women was breast cancer (15.3%) and for men was prostate cancer (10.1%). Colon cancer was the third leading cause of death from cancer both for men (9.4%) and women (10.1%). † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. § Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenzaassociated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, VectorBorne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Data for H. influenzae (all ages, all serotypes) are available in Table II . † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. § § Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. A total of 70 cases were reported for the 2006-07 flu season. ¶ ¶ No measles cases were reported for the current week. *** Data for meningococcal disease (all serogroups) are available in Table II. † † † No rubella cases were reported for the current week. § § § Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. Pacific  17  12  92  494  826  8  10  106  360  365  2  2  11  86  65  Alaska  -0  1  3  1  -0  3  4  4  -0  1  --California  13  10  40  430  784  6  8  31  273  298  1  1  11  63  65  Hawaii  -0  2  4  10  -0  1  2  6  -0  1  1  -Oregon§   -1  2  21  31  -1  5  45  57  -0  1  6  -Washington  4  0  52  36  -2  0  74  36  -1  0  2 16 - 1  0  0  1  --0  2  -2  -0  2  9  9  Louisiana  -0  1  2  --0  2  14  6  -0  4  24  32  Oklahoma  -0  0  ---0  3  5  7  -0  4  14  8  Texas§   -1  5  3 8  1 6  -1  2 5  4 3  6 7  -0  1 1  3 1  3 2   Mountain  1  1  3  31  20  2  1  6  41  58  1  1  4  46  58  Arizona  -0  1  2  7  -0  3  7  19  -0  2  9  14  Colorado  1  0  1  2  -2  0  2  14  13  1  0  2  17  19  Idaho§   -0  2  7  3  -0  2  2  1  -0  1  3  3  Montana§   -0  1  2  --0  1  3  2  -0  1  1  4  Nevada§   -0  2  7  2  -0  1  2  2  -0  1  4  5  New Mexico§   -0  1  3  3  -0  1  3  5  -0  1  2  3  Utah  -0  2  5  4  -0  3  10  16  -0  2  8  6  Wyoming§   -0  1  3  1  -0  0  ---0  1  2  4   Pacific  9  2  16  115  66  10  3  45  124  161  4  4  48  184  194  Alaska  -0  1  4  2  -0  1  2  23  -0  1  1  3  California  9  2  9  107  58  7  2  7  86  121  3  3  10  131  149  Hawaii  N  0  0  N  N  -0  1  2  8  -0  2  7  7  Oregon§   -0  1  3  6  1  0  3  13  9  -0  3  27  35  Washington  -0  8  1  -2  0  43  21  -1  0  43 1  20  226  671  611  -2  34  69  721  13  1  168  139  100  Arkansas†   -2  17  113  67  -0  5  24  24  13  0  53  72  46  Louisiana  -0  1  14  22  -0  1  -5  -0  1  2  3  Oklahoma  -0  36  5  18  -0  22  45  52  -0  108  45  28  Texas†   1  17  174  539  504  -0  32  -640  -0  7  20  23   Mountain  5  24  61  779  2,015  -3  28  155  172  1  0  4  28  41  Arizona  -5  13  159  413  -2  12  109  110  1  0  2  6  10  Colorado  4  6  17  216  614  -0  0  ---0  2 3  1  11  76  91  1  0  3  9  18  -0  1  2  2  Washington  19  1  377  142  --0 
SOURCE:
- - - 1 1 - 1 1 SARS-CoV §, § § § - - - - - - 8 N Smallpox § - - - - - - - - StreptococcalN 0 0 N N - 0 0 - - American Samoa U 0 32 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 5 207 340 658 - 0 0 - - - 0 0 - - PuertoAmerican Samoa U 0 0 U U U 0 2 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - - 1American Samoa U 0 0 U U U 0 0 U U U 0 0 U U C.N.M.I. U - - U U U - - U U U - - U U Guam - 0 0 - - - 0 0 - - - 0 0 - - Puerto
